UNSPSC 51282936: Pazufloxacin

This classification denotes a quinolone antibiotic with the molecular formula C16H15FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CZ1R38NDI, chemically known as 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (s)- but generally known as pazufloxacin, which bears US NIH Compound Identifier 65957. European Medicines Agency schedules Pazufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09641MIG.

UNSPSC 51282936 Pazufloxacin is a Commodity code; however, the recent state and local opportunities posted under this code show little relevance to the pharmaceutical product itself. The code nominally describes a specific fluoroquinolone antibiotic, yet the four most-recent state-local solicitations tied to it span naloxone procurement, direct-to-manufacturer prescription programs, general medical and first aid supplies, and multi-source generic pharmaceuticals and OTC products — none of which target pazufloxacin specifically. State and local procurement offices appear to be using this code as a placeholder or catch-all taxonomy marker for broader pharmaceutical and medical supply categories rather than as a specific-product identifier. This mismatch suggests either a tagging error in the underlying procurement database or a jurisdictional practice of assigning high-level drug codes to commodity bundles that may include the specific agent nominally described.

The issuing bodies span state health departments, county health systems, municipal fire departments, and multi-state cooperative purchasing alliances. Recent opportunities include Seminole County, Florida (naloxone and drug deactivation systems, IFB, due July 26, 2023); Texas Health and Human Services Commission (direct-to-manufacturer prescription program, RFI, closed April 3, 2026); City of Tampa (medical and first aid supplies, IFB, due March 13, 2026, estimated $700,000 with small-business enterprise set-aside); and Minnesota Multistate Cooperative Purchasing Alliance (generic multi-source pharmaceuticals and OTC products, RFP, due March 26, 2026). Geographic activity appears concentrated in Florida, Texas, and the upper Midwest, with the cooperative purchasing vehicle extending to Oregon. Without reliable alignment between the code and actual scope, business development professionals should treat this code as a low-signal taxonomy entry and confirm the specific product or category requirements directly in each opportunity notice rather than relying on the code name alone.